News from insmed incorporated A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Feb 22, 2019, 07:30 ET Insmed Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...


Feb 20, 2019, 08:00 ET Insmed to Present at the Leerink Partners 8th Annual Global Healthcare Conference

Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...


Feb 15, 2019, 08:00 ET Insmed to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call on Friday, February 22, 2019

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...


Feb 04, 2019, 16:05 ET Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...


Jan 07, 2019, 16:05 ET Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...


Jan 04, 2019, 16:05 ET Insmed Provides Update on ARIKAYCE® (amikacin liposome inhalation suspension) U.S. Launch and Outlines Strategic Priorities for 2019

Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare...


Dec 13, 2012, 08:00 ET Insmed to Present at 31st Annual J.P. Morgan Healthcare Conference

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing and commercializing novel, targeted inhaled therapies for...


Nov 13, 2012, 08:00 ET Insmed Announces CLEAR-108 Phase 3 Clinical Study of ARIKACE® in Cystic Fibrosis Patients with Pseudomonas Lung Infections Has Completed Target Enrollment

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today ...


Nov 12, 2012, 08:00 ET Insmed To Present At Two Upcoming Investor Conferences

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today ...


Nov 07, 2012, 07:15 ET Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2012

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the...


Nov 07, 2012, 07:00 ET Insmed Appoints 15-Year Life Sciences Industry Veteran Andrew Drechsler as Chief Financial Officer

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today ...


Oct 24, 2012, 08:00 ET Insmed to Host 2012 Third Quarter Earnings Conference Call

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing novel inhalation therapeutics for patients suffering from...


Sep 28, 2012, 08:23 ET Insmed Announces Pricing of Approximately $26 Million Direct Public Offering

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing novel inhalation therapeutics for patients suffering from...


Aug 30, 2012, 08:00 ET Insmed to Present at Stifel Nicolaus 2012 Healthcare Conference

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the...


Aug 14, 2012, 08:00 ET Insmed to Present at 2012 Wedbush PacGrow Life Sciences Management Access Conference

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the...


Aug 07, 2012, 07:00 ET Insmed Announces Financial Results For Second Quarter And Six-months Ended June 30, 2012

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the...


Aug 06, 2012, 08:00 ET Pharmaceutical Industry Veteran Al Altomari Elected To Insmed's Board Of Directors

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today ...


Aug 02, 2012, 08:00 ET Insmed Receives Second Composition Of Matter Patent For ARIKACE®

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today ...


Jul 30, 2012, 08:00 ET Insmed Announces Planned Departure Of Chief Financial Officer

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today ...


Jul 24, 2012, 08:00 ET Insmed to Host 2012 Second Quarter Earnings Conference Call

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, will...


Jul 10, 2012, 08:00 ET Insmed To Present At JMP Securities 7th Annual Healthcare Conference

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today ...


Jul 02, 2012, 08:00 ET Insmed Secures $20 Million Loan Agreement With Hercules Technology Growth Capital

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today ...


Jun 27, 2012, 08:00 ET Insmed Announces First Patient Dosed in TARGET-NTM Phase 2 Clinical Trial of ARIKACE® in Patients with Non-Tuberculous Mycobacteria (NTM) Lung Disease

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that the first patient has been dosed in the Company's U.S. phase ...


May 30, 2012, 08:00 ET Insmed Provides Corporate Update

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today provided a corporate update, including the Company's current strategic...


May 23, 2012, 08:00 ET Insmed Incorporated Begins Screening Patients For TARGET-NTM U.S. Clinical Trial Of ARIKACE® In Patients With Non-tuberculous Mycobacterial Lung Disease

Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that it has begun screening patients for its U.S. phase 2...